Thérapies de Conversion

Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.

Hepatology . 2025;82 (3) :E105-E106

Résumé

Tous les articles